Journal Article

Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial

Su, Yi, Ríos-Romenets, Silvia, Sánchez, Gregorio, Poon, Victor, Langbaum, Jessica B, Lopera, Francisco S, Selkoe, Dennis J, Reiman, Eric M, Doody, Rachelle S, Collazos, Mario Muñoz, Espinosa, Alejandro, Chen, Kewei, Castaño, Marisol Londoño, Schneider, Andres, Muñoz, Claudia, Nguyen, Jonas, Xu, Yi Ran, Tirado, Victoria, Cai, Yuqi, Hu, Nan, Giraldo-Chica, Margarita, Villegas, Gustavo, Lopez, Hugo, Acosta-Baena, Natalia, Bocanegra, Yamile, Ostaszewski, Beth, Alexander, Robert C, Ashton, Nicholas J, Quiroz, Yakeel T, Sink, Kaycee M, Clayton, David, Schneider, Lon S, Bittner, Tobias, Thomas, Ronald G, Cardona, Eugenia, Dolton, Michael, Denkinger, Marisa N, Ospina, Paula, Aguillón, David, Henao, Eliana, Luna, Ernesto, Alvarez, Sergio, Tariot, Pierre N, Jakimovich, Laura J

2026

Overview

To have maximal benefit, Alzheimer's disease-modifying treatments might need to be started before the onset of clinical symptoms. Mutations of the PSEN1 gene are inherited as fully penetrant, autosomal-dominant traits, which almost always result in the clinical onset of Alzheimer's disease before the age of 65 years. We aimed to evaluate the efficacy, including possible delayed emergence of cognitive impairment, and safety of crenezumab, an anti-amyloid monoclonal antibody, in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at high imminent risk of developing symptoms due to Alzheimer's disease. This 5–8-year common-close, double-blind, placebo-controlled, single-centre trial screened kindred members aged 30–60 years from the main health-care site in Medellín, Colombia. Participants who were cognitively unimpaired and carried the PSEN1Glu280Ala autosomal-dominant mutation were randomly assigned 1:1 to receive placebo or subcutaneous crenezumab (investigators and participants were masked to treatment allocation), with an initial 300 mg dose every 2 weeks that increased to 720 mg every 2 weeks, and a later optional increase to 60 mg/kg intravenously every 4 weeks. Randomisation was stratified by age, education, APOE ɛ4 carrier status, and baseline Clinical Dementia Rating. Mutation non-carriers received placebo and were included in a 1:2 ratio of non-carriers to carriers to maintain genotype masking and include a genetic kindred control. Dual primary outcomes were the annualised rates of change in the Alzheimer's Prevention Initiative (API) preclinical autosomal-dominant Alzheimer's disease (ADAD) composite test total score and Free and Cued Selective Reminding Test–Cueing Index (FCSRT–CI) assessed in randomised participants who received at least one dose of the study drug, according to treatment assignment. Primary endpoints were assessed with a random coefficient regression model with a missing-at-random assumption adjusting for randomisation factors. Safety endpoints for mutation carriers were assessed in randomised participants who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov (NCT01998841) and is completed. 619 Colombian API registrants were prescreened, 315 were assessed for eligibility, and 252 were enrolled (crenezumab–carrier, n=85; placebo–carrier, n=84; placebo–non-carrier, n=83; 160 [63%] women and 92 [37%] men) between Dec 20, 2013, and Feb 27, 2017. 237 (94%) completed the trial, with final data collection on March 22, 2022. The annualised rate of change in the API ADAD composite was –1·10 (SE 0·29) in the crenezumab group and –1·43 (0·29) in the placebo group (between-group difference 0·33 [95% CI –0·48 to 1·13]; p=0·43). The annualised rate of change in FCSRT–CI was –0·03 (0·00) in the crenezumab group and –0·04 (0·00) in the placebo group (between-group difference 0·01 [0·00 to 0·02]; p=0·16). All participants had at least one adverse event; serious adverse events occurred in 23 (27%) of 84 in the crenezumab group and 21 (25%) of 84 in the placebo group. No fatalities occurred. Crenezumab therapy administered for 5–8 years did not result in significant benefits on our primary clinical outcomes in cognitively unimpaired participants predisposed to developing ADAD dementia; secondary and exploratory outcomes also showed no significant effect on removal of amyloid plaques or other clinical or biomarker outcomes. Together with the results of other anti-amyloid β trials, robust fibrillar amyloid removal appears necessary for clinical efficacy in people with elevated brain amyloid. This study will further inform the biomarker, cognitive, and clinical trajectory of preclinical ADAD, the risk of clinical progression in amyloid-positive and amyloid-negative mutation carriers, and the size and design of future secondary and primary prevention trials. US National Institute on Aging (NIA), Banner Alzheimer's Institute, Genentech, F Hoffmann-La Roche.

• Publisher: Elsevier Ltd
• Subject: Neurology